Research results from Institute Krems Bioanalytics of IMC Krems and Takeda will help to treat patients suffering from hemophilia A more effectively.
Krems, Austria, 22. November 2022: Immune responses against Factor VIII, which is used to treat hemophilia A (bleeding disorder), are influenced by the microenvironment of antigen presenting cells. This is the result of a scientific study conducted in cooperation between the Institute Krems Bioanalytics of IMC University of Applied Sciences Krems and the international pharmaceutical company Takeda, which was recently published in the journal Frontiers in Immunology. In this study, a cell culture model was used to investigate the impact of the microenvironment on factor VIII uptake and processing in antigen presenting cells. The observed alterations in protein processing might have profound effects on immune responses to FVIII. The novel data provide the basis for the development of future FVIII therapies that elicit minimal immune responses in patients.
Hemophilia A is a hereditary bleeding disorder caused by absence or deficiency of active clotting factor VIII (FVIII) in the blood. Patients are therefore treated with FVIII replacement therapy. A major complication of this therapy is the development of a neutralizing immune reaction in 30% of the patients, thereby rendering the administered FVIII ineffective. Why such a complication occurs in some people while others are spared is not yet clear – and it is precisely this issue that the research group from Takeda and IMC Krems led by Dr. Christian Lubich set out to address.
Adverse Immune Response
“The experimental design of our cell culture study,” Dr. Lubich stated, “was aimed at taking a closer look at the response of different immune cells in the context of FVIII administration and thereby gaining better insight into the underlying processes.” And indeed, the study data suggest a crucial link between the specific microenvironment during FVIII uptake by specific immune cells – so-called antigen-presenting cells (APCs) – and the FVIII proteins (antigens) presented by these cells on their cell surface. Depending on the microenvironment, the composition of these surface proteins differs and thus also influences the specificity of the subsequently activated CD4+T cells, partly resulting in the undesired neutralizing immune response.
To verify the relevance of the data in vivo as well, it would now be useful to conduct a follow-up study in humans. Dr. Lubich and his team at the Institute of Krems Bioanalytics already have an idea for this, based on a promising new technology: “Immunopetidomics is a pioneering method for investigation of the composition and dynamics of proteins presented by antigen-presenting cells with the aid of mass spectrometry. This method can be used, for example, to determine peptides of a pathogen, a tumor cell or, as in this case, a biotherapeutic agent that elicit an immune response. This platform will therefore not only help to better understand adverse reactions of the immune system to biotherapeutics, but will also enable the identification of important antigens for the development of immunotherapies.”
The Institute Krems Bioanalytics of the IMC University of Applied Sciences Krems offers contract research for industry and academic institutions since 2014. Specialized in innovative bioanalytical services, the institute has strong expertise in tailor-made immunogenicity assessments to characterize the immunogenic potential of therapeutic proteins and vaccines. Data are collected in preclinical and clinical studies and are used by regulatory authorities for drug and vaccine evaluation and assessment. In order to generate scientifically sound and robust data and ensure data integrity, quality assurance is carried out according to the industry standards Good Laboratory Practice (GLP) and Good Clinical Practice (GCP). The quality assurance system is regularly audited by the Austrian Agency for Health and Food Safety (AGES), by international regulatory authorities or by the pharmaceutical industry. This makes the Institute Krems Bioanalytics one of the few facilities in Austria that can offer high quality-assured contract research for the pharmaceutical industry at the highest level.
Original Publication: Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells. Christian Lubich, Katharina N. Steinitz, Brigitte Hoelbl, Thomas Prenninger, Pauline M. van Helden, Markus Weiller, Birgit M. Reipert. Frontiers in Immunology. DOI 10.3389/fimmu.2022.975680
IMC Krems at a glance
Located in the heart of the province of Lower Austria, IMC Krems is committed to promoting internationalisation, practically focused education and innovation. It has 160-plus partner universities, in excess of 1,000 partner companies worldwide and over 3,000 students from 90 countries spread across two locations in Austria, with another 700 studying at five sites abroad. The contemporary topics of sustainability and digitalisation feature prominently in all of the degree programmes at this dynamic, modern institution. IMC Krems offers 27 full-time and part-time bachelor and master degree programmes and four continuing education courses in its core subjects of business, digitalisation and engineering, health sciences, and life sciences. The university has strong links with research and business – total funding for the university’s numerous research projects currently amounts to several million euros. English and German as the languages of instruction, internships in Austria and overseas, as well as international exchange programmes and semesters abroad ensure that students are equipped with all the tools they need for careers in Austria or other countries. Outstanding performance: IMC Krems’ excellent reputation in Austria and abroad is reflected in numerous external distinctions (CHE Ranking, IQNet and Quality Austria for fulfilment of ISO standards, Diploma Supplement Label), certificates (evalag), membership of international organisations (FHK, AACSB, ÖAWI, EAIE), and accreditations from international organisations.
Visit the IMC Krems website for the latest facts and figures about the university: https://www.fh-krems.ac.at/fachhochschule/medienportal/presse/#facts-figures.
Dr. Christian Lubich
Deputy Head of Institute Krems Bioanalytics IMC University of Applied Sciences Krems
3500 Krems / Austria
M +43-(0)664-855 37 10
Marketing and Public Relations
3500 Krems / Austria
T +43 2732 802 530
Copy Editing & Distribution
PR&D – Public Relations for Research & Education
Dr. Barbara Bauder
3400 Klosterneuburg / Austria
T +43 664 1576 350